Table 1 Properties of the examined cell lines, TTFields treatment conditions, cellular cytotoxic response to TTFields, and the different transcriptomics methods employed for each dataset.

Tumor type (abbreviation)	Cell line	Tumor origin	Donor sex	Growth mode	Doubling time [h]	TTFields treatment					Transcriptomics method	Ref
						Frequency [kHz]	Intensity [V/cm RMS]	Duration [h]	Cell count [% of control]
						Frequency [kHz]	Intensity [V/cm RMS]	Duration [h]	24 h	48 h
Gastric cancer (GasC)	AGS	Primary	Female	Adherent	32	150	1.7	24, 48	74	30	PolyA RNA-seq with Unique Molecular Identifiers (UMI)	^b
Gastric cancer (GasC)	KATOIII	Metastatic	Male	Adherent	27	150			85	61
Pancreatic cancer (PanC)	AsPC1	Primary	Female	Adherent	33	150			79	62
Pancreatic cancer (PanC)	BxPC3	Metastatic	Female	Adherent	45	150			72	49
Ovarian cancer (OvaC)	OVCAR3	Metastatic	Female	Adherent	54	200			64	41
Non-small cell lung carcinoma (NSCLC)	A549	Primary	Male	Adherent	22	150 ^a	1.5	12, 24, 48	88	47	Illumina Whole Genome HumanWG6 v4 Expression BeadChips	[18]
	H1299	Metastatic	Male	Adherent	20				83	75
	H157	N/A	Male	Adherent	36				96	33
	H1650	Metastatic	Male	Adherent	26				95	84
	HCC4006	Metastatic	Male	Adherent	34				106	87
Pleural Mesothelioma (Meso)	CD473	Primary	Male	Adherent	42	150	1.1	8, 24, 48	64	42	Whole RNA-seq	[30]
Pleural Mesothelioma (Meso)	CD60	Primary	Female	Adherent	44	150	1.1	8, 24, 48	73	73	Whole RNA-seq	[30]
Glioblastoma (GBM)	GBM1	Primary	Male	Neurospheres	62	200	1.7	48	N/A	84	PolyA RNA-seq	^c
	JHH520	Primary	Female	Neurospheres	56				N/A	71
	NCH644	Primary	Female	Neurospheres	102				N/A	73
	SF188	Primary	Male	Neurospheres	37				N/A	75

^aNot all were treated at the same frequency, specific details may be found in the original publication of the datasets.
^bConducted by Novocure LTD, Haifa, Israel.
^cConducted by Renfei Du and Ulf Kahlert.

Quick links

Search